 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for HEBP2 |
 Gene summary |
| Basic gene information | Gene symbol | HEBP2 |
| Gene name | heme binding protein 2 | |
| Synonyms | C6ORF34B|C6orf34|PP23|SOUL | |
| Cytomap | UCSC genome browser: 6q24 | |
| Type of gene | protein-coding | |
| RefGenes | NM_014320.2, | |
| Description | heme-binding protein 2placental protein 23 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 605825 | |
| HGNC : HGNC | ||
| HPRD : 09316 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_HEBP2 | |
| BioGPS: 23593 | ||
| Pathway | NCI Pathway Interaction Database: HEBP2 | |
| KEGG: HEBP2 | ||
| REACTOME: HEBP2 | ||
| Pathway Commons: HEBP2 | ||
| Context | iHOP: HEBP2 | |
| ligand binding site mutation search in PubMed: HEBP2 | ||
| UCL Cancer Institute: HEBP2 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | BreastBone marrow | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | BRCALAML | |
| Reference showing the relevant tissue of HEBP2 | ||
| Description by TissGene annotations | TissgsLTS | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for HEBP2 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| LUSC | 0.174053563 | -0.826766045 | 1.000819608 | 5.71E-15 | 3.49E-14 |
| Top |
| TissGene-miRNA for HEBP2 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for HEBP2 |
| TissGeneSNV for HEBP2 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.Q196P | HNSC | 1 |
| p.P112H | LUSC | 1 |
| p.K82T | COAD | 1 |
| p.D118N | SARC | 1 |
| p.Y43C | THYM | 1 |
| p.E153X | READ | 1 |
| p.N190S | STAD | 1 |
| p.D126H | LUSC | 1 |
| p.A133S | STAD | 1 |
| p.P112S | SKCM | 1 |
| p.D170N | UCEC | 1 |
| p.E134* | STAD | 1 |
| p.M56I | ACC | 1 |
| p.R111K | STAD | 1 |
| p.G96C | KIRP | 1 |
| Top |
| TissGeneCNV for HEBP2 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for HEBP2 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | ChiTaRs | NA | BM968067 | HEBP2-JMJD1C | chr6:138734291 | chr10:65043429 |
| Top |
| TissGeneNet for HEBP2 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| HEBP2, PDCD6, LRPPRC (tumor) | HEBP2, PDCD6, LRPPRC (normal) |
 |  |
| Top |
| TissGeneProg for HEBP2 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for HEBP2 |
| TissGeneDrug for HEBP2 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for HEBP2 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0023903 | Liver neoplasms | 1 | CTD_human |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |